Sanofi Canada is the Canadian affiliate of Sanofi, one of the world’s leading healthcare companies.
As a leading healthcare partner, Sanofi provides medicines in several therapeutic areas, mainly diabetes, oncology and cardiovascular disease.
The comapny is also active in consumer healthcare, through its affiliate Sanofi Consumer Health.
Sanofi’s sister company, Sanofi Pasteur, is Canada’s largest vaccines producer. Together the two companies employ closse to 1,700 people across the country and, with investments of $151.7 million in 2011, are among the country’s top spenders in biopharmaceutical research and development.
2905 Place Louis-R.-Renaud
Laval, Quebec, H7V 0A3
514-331-9220
1-800-363-6364
Niven Al-Khoury, President of Sanofi Canada, highlights the strong presence that Sanofi has established in the country over the past 100 years, some of the notable historical achievements from collaboration…
The President & CEO of Sanofi Canada talks candidly about the pros and cons of the current administrative setup of the Canadian healthcare sector; Concerto, an association in Quebec that…
Drs Neil Cashman and Larry Altstiel of ProMIS Neurosciences weigh in on recent progress towards an effective therapy for Alzheimer’s disease, potentially representing a break from three decades of scientific…
Some of the top stories coming out of Canadian healthcare and life sciences, including a new GSK flu vaccine deal, Amylyx Pharmaceuticals’ first approval for an ALS drug, and the…
In April, the Canadian Ministry of Health announced the government would not be proceeding with certain proposed amendments to the Patented Medicines Regulations which govern the Patented Medicine Prices Review…
In conversation in the October edition of DIA’s Global Forum magazine, Canadian Agency for Drugs and Technologies in Health (CADTH) CEO Suzanne McGurn highlights how the work of HTA bodies…
Writing in the September edition of DIA’s Global Forum magazine, Dr Judith Glennie examines the specific steps that have been taken in the journey towards a National Pharmacare program in…
Writing in the March edition of DIA’s Global Forum magazine, Judith Glennie examines the findings of Health Canada’s consultation with Canadians on what a national strategy for high-cost rare disease…
Clint Sharples, CEO of Heritage Cannabis, gives a potted history of the medical cannabis industry in Canada, its current legal status, provincial variations in patient registrations, financial performance, the impact…
As the only country in the world to boast a universal healthcare system that does not cover prescription drugs, Canada has been struggling with the concept of ‘national pharmacare’ for…
The latest news from Canadian pharma including deals for J&J’s and Novavax’s COVID-19 vaccines, an abrupt end to Canada’s participation in CanSino Biologics’ clinical trials the country’s first medical cannabis…
Pushback from drug companies on Canada’s newest drug pricing regulations has led the country’s regulatory body to reconsider their implementation. Companies cite the push for cost-effectiveness as a reason for…
Dr Neil Cashman looks at the potential impact of US FDA approval for Biogen’s aducanumab on the search for Alzheimer’s Disease (AD) treatments, and how Canada is playing a leading…
John L. Wallace of Antibe Therapeutics highlights how Canadian innovation stands to put the country at the forefront of the next wave of global biopharmaceutical R&D. BlueRock Therapeutics, a promising…
See our Cookie Privacy Policy Here
